Advisory Boards

Seattle Cancer Consortium Breast SPORE

Advisory Boards

One of the most essential features of the SPORE structure is the ongoing evaluation of scientific progress by the executive committee (leaders, directors and advocates) and periodic review from members of Internal and External Advisory Boards  (EAB/IAB) who provide feedback and guidance. The EAB and IAB address and advise on scientific direction, overall planning, and evaluation of the translational progress of SPORE projects and activities.  

External Board

Christine Ambrosone, PhD, brings expertise in molecular epidemiology to the SPORE. She is Professor of Oncology, Chair of the Department Cancer Prevention and Control in the Division of Cancer Prevention and Population Sciences, and co-leader of the CCSG Population Sciences Program at Roswell Park Cancer Institute.

Gabriel Hortobagyi, MD, FACP, is an internationally recognized expert on the use of systemic therapy for the treatment of breast cancer. He is Professor of Medicine and Chair Emeritus, Nellie B. Connally Chair in Breast Cancer and Program Director of the Susan G. Komen Interdisciplinary Breast Fellowship Program in the Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center.

Elizabeth Jaffee, MD, is a leader in immune-based therapies for the treatment of pancreatic and breast cancers. She is Professor of Oncology and Deputy Director of the Clinical and Translational Research Institute at the Johns Hopkins University and Deputy Director and Associate Director for Translational Research, and co-director of the Immunology Program of the Johns Hopkins Kimmel Cancer Center.

John Minna, MD, has directed the Lung Cancer SPORE (P50CA70907) at UTSMC for the past 17 years and is a leader in molecular genetics research for lung cancer. He is Professor of Medicine and Pharmacology and Director of the Hamon Center for Therapeutic Oncology Research at the University of Texas Southwestern Medical Center (UTSMC) and Director of the Hamon Center for Therapeutic Oncology Research and the W.A. "Tex" & Deborah Moncrief Jr. Center for Cancer Genetics at UTSMC.

Eric Winer, MD, is a world-renowned leader in breast cancer clinical trials. He is Professor of Medicine at Harvard Medical School and Chair of the Executive Committee for Clinical Programs, Chief of the Division of Women's Cancers, Director of the Breast Oncology Program at the Susan F. Smith Center for Women's Cancers, Thompson Chair in Breast Cancer Research, and Institute Physician at Dana-Farber Cancer Institute. Dr. Winer directs the Dana-Farber/Harvard SPORE in Breast Cancer (P50CA168504).

Internal Board

The SPORE Executive Committee members are aided in their work by the Internal Advisory Board (IAB), composed of senior scientists at the Fred Hutch and UW. The IAB provides guidance and advice in the form of critical assessment of the scientific direction and function of the SPORE. Members of the committee form a pool of expertise from which the EC and the CEP and DRP committees draw as needed.  

Frederick Appelbaum, MD, is a hematological oncologist with an international reputation for clinical and basic research on hematologic malignancies and, particularly, the value of bone marrow transplantation in those diseases. He is Executive Vice President and Deputy Director, External Affairs and Member of the Clinical Research Division, FHCRC, and Executive Director and President of the Seattle Cancer Care Alliance (SCCA). He also holds the rank of Professor and Head, Division of Medical Oncology, UW.

Eric Holland, MD, PhD, is a neurosurgeon who focuses his research on molecular mechanisms underlying the pathogenesis of CNS tumors, preclinical modeling and translation to human CNS cancers. He is Senior Vice President and Director, Human Biology Division and Solid Tumor Translational Research at FHCRC; Director, Nancy and Buster Alvord Brain Tumor Center and Chap and Eve Alvord and Elias Alvord Chair in Neuro-Oncology, UW Medicine.

Peter Nelson, MD, is a medical oncologist conducting research on neoadjuvant treatment strategies for prostate carcinoma. He is a member in the Human Biology and Clinical Research Divisions, FHCRC, Professor of Medicine at the UW, Co-Head of the Program in Prostate Cancer for the Consortium, and Director of Genitourinary Oncology Clinical research at SCCA. He is PI of the Pacific Northwest Prostate SPORE.

Nicole Urban, ScD, is a population scientist developing methods to improve the use, performance, and efficacy of breast and ovarian cancer screening tools. She is a Health Services Research Professor, UW and a Member, Translational Research Program, Public Health Sciences Division, FHCRC. Along with Dr. Porter, she serves as Co-Program Head of the Women’s Cancer Research Program for the Consortium, and is PI of the Pacific Ovarian Cancer Research Consortium SPORE.

Edus (Hootie) Warren, MD, PhD, is an oncologist specializing in allogeneic hematopoietic cell transplantation (HCT) as well as an immunologist with a focus on graft-versus-host disease and the graft-versus-leukemia effect that occur after allogeneic HCT. He is a Member, Program in Immunology, Clinical Research Division, FHCRC, and Professor of Medicine, UW.